Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada.
Chiropractic Department, D'Youville University, Buffalo, NY, USA.
Syst Rev. 2024 Sep 12;13(1):232. doi: 10.1186/s13643-024-02654-6.
In recent studies, receipt of chiropractic care has been associated with lower odds of receiving prescription opioids and, among those already prescribed, reduced doses of opioids among patients with non-cancer spine pain. These findings suggest that access to chiropractic services may reduce reliance on opioids for musculoskeletal pain.
To assess the impact of chiropractic care on initiation, or continued use, of prescription opioids among patients with non-cancer spine pain.
We will search for eligible randomized controlled trials (RCTs) and observational studies indexed in MEDLINE, Embase, AMED, CINAHL, Web of Science, and the Index to Chiropractic Literature from database inception to June 2024. Article screening, data extraction, and risk-of-bias assessment will be conducted independently by pairs of reviewers. We will conduct separate analyses for RCTs and observational studies and pool binary outcomes (e.g. prescribed opioid receipt, long-term opioid use, and higher versus lower opioid dose) as odds ratios (ORs) with associated 95% confidence intervals (CIs). When studies provide hazard ratios (HRs) or relative risks (RRs) for time-to-event data (e.g. time-to-first opioid prescription) or incidence rates (number of opioid prescriptions over time), we will first convert them to an OR before pooling. Continuous outcomes such as pain intensity, sleep quality, or morphine equivalent dose will be pooled as weighted mean differences with associated 95% CIs. We will conduct meta-analyses using random-effects models and explore sources of heterogeneity using subgroup analyses and meta-regression. We will evaluate the certainty of evidence of all outcomes using the GRADE approach and the credibility of all subgroup effects with ICEMAN criteria. Our systematic review will follow the PRISMA statement and MOOSE guidelines.
Our review will establish the current evidence informing the impact of chiropractic care on new or continued prescription opioid use for non-cancer spine pain. We will disseminate our results through peer-reviewed publication and conference presentations. The findings of our review will be of interest to patients, health care providers, and policy-makers.
Systematic review registration: PROSPERO CRD42023432277.
在最近的研究中,接受脊医治疗与接受处方类阿片类药物的可能性降低以及已经开出处方药的患者的阿片类药物剂量减少有关,这些患者患有非癌症脊柱疼痛。这些发现表明,获得脊医服务可能会减少对肌肉骨骼疼痛使用阿片类药物的依赖。
评估脊医治疗对非癌症脊柱疼痛患者开始或继续使用处方类阿片类药物的影响。
我们将搜索符合条件的随机对照试验(RCT)和观察性研究,这些研究将在 MEDLINE、Embase、AMED、CINAHL、Web of Science 和脊医文献索引中进行,从数据库建立到 2024 年 6 月。文章筛选、数据提取和偏倚风险评估将由两对评审员独立进行。我们将对 RCT 和观察性研究进行单独分析,并将二项结局(例如开具阿片类药物处方、长期使用阿片类药物和更高或更低的阿片类药物剂量)作为优势比(OR)与相关 95%置信区间(CI)进行汇总。当研究提供时间事件数据(例如首次开具阿片类药物处方的时间)或发生率(一段时间内开具的阿片类药物处方数量)的风险比(HR)或相对风险(RR)时,我们将首先将其转换为 OR 后再进行汇总。疼痛强度、睡眠质量或吗啡等效剂量等连续结局将以加权均数差与相关 95%CI 进行汇总。我们将使用随机效应模型进行荟萃分析,并使用亚组分析和元回归探索异质性的来源。我们将使用 GRADE 方法评估所有结局的证据确定性,并使用 ICEMAN 标准评估所有亚组效果的可信度。我们的系统评价将遵循 PRISMA 声明和 MOOSE 指南。
我们的综述将确定脊医治疗对非癌症脊柱疼痛患者新的或持续使用处方类阿片类药物的影响的现有证据。我们将通过同行评审出版物和会议演讲来传播我们的结果。本综述的结果将引起患者、医疗保健提供者和政策制定者的兴趣。
系统评价注册:PROSPERO CRD42023432277。